Novel read through agent: ZKN-0013 demonstrates efficacy in APC min model of familial adenomatous polyposis.

Autor: Graf MR; Eloxx Pharmaceuticals, Watertown, MA, 02472, USA., Apte S; Eloxx Pharmaceuticals, Watertown, MA, 02472, USA., Terzo E; Eloxx Pharmaceuticals, Watertown, MA, 02472, USA., Padhye S; Eloxx Pharmaceuticals, Watertown, MA, 02472, USA., Shi S; Eloxx Pharmaceuticals, Watertown, MA, 02472, USA., Cox MK; Eloxx Pharmaceuticals, Watertown, MA, 02472, USA., Clark RB; Eloxx Pharmaceuticals, Watertown, MA, 02472, USA., Modur V; Eloxx Pharmaceuticals, Watertown, MA, 02472, USA., Badarinarayana V; Eloxx Pharmaceuticals, Watertown, MA, 02472, USA. vbadarinarayana@eloxxpharma.com.
Jazyk: angličtina
Zdroj: Journal of molecular medicine (Berlin, Germany) [J Mol Med (Berl)] 2023 Apr; Vol. 101 (4), pp. 375-385. Date of Electronic Publication: 2023 Feb 20.
DOI: 10.1007/s00109-023-02291-x
Abstrakt: Familial adenomatous polyposis (FAP) is a precancerous, colorectal disease characterized by hundreds to thousands of adenomatous polyps caused by mutations in the tumor suppressor gene adenomatous polyposis coli (APC). Approximately 30% of these mutations are premature termination codons (PTC), resulting in the production of a truncated, dysfunctional APC protein. Consequently, the β-catenin degradation complex fails to form in the cytoplasm, leading to elevated nuclear levels of β-catenin and unregulated β-catenin/wnt-pathway signaling. We present in vitro and in vivo data demonstrating that the novel macrolide, ZKN-0013, promotes read through of premature stop codons, leading to functional restoration of full-length APC protein. Human colorectal carcinoma SW403 and SW1417 cells harboring PTC mutations in the APC gene showed reduced levels of nuclear β-catenin and c-myc upon treatment with ZKN-0013, indicating that the macrolide-mediated read through of premature stop codons produced bioactive APC protein and inhibited the β-catenin/wnt-pathway. In a mouse model of adenomatous polyposis coli, treatment of APC min mice with ZKN-0013 caused a significant decrease in intestinal polyps, adenomas, and associated anemia, resulting in increased survival. Immunohistochemistry revealed decreased nuclear β-catenin staining in the epithelial cells of the polyps in ZKN-0013-treated APC min mice, confirming the impact on the β-catenin/wnt-pathway. These results indicate that ZKN-0013 may have therapeutic potential for the treatment of FAP caused by nonsense mutations in the APC gene. KEY MESSAGES: • ZKN-0013 inhibited the growth of human colon carcinoma cells with APC nonsense mutations. • ZKN-0013 promoted read through of premature stop codons in the APC gene. • In APC min mice, ZKN-0013 treatment reduced intestinal polyps and their progression to adenomas. • ZKN-0013 treatment in APC min mice resulted in reduced anemia and increased survival.
(© 2023. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature.)
Databáze: MEDLINE
Externí odkaz: